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Abstract 
Background: Entry of human immunodeficiency virus type 1 (HIV-1) into cells involves the interaction of the viral 
gp120 envelope glycoproteins (Env) with cellular CD4 and a secondary coreceptor, which is typically one of the 
chemokine receptors CCR5 or CXCR4. CCR5-using (R5) HIV-1 strains that display reduced sensitivity to CCR5 antago-
nists can use antagonist-bound CCR5 for entry. In this study, we investigated whether naturally occurring gp120 
alterations in HIV-1 subtype C (C-HIV) variants exist in antiretroviral therapy (ART)-naïve subjects that may influence 
their sensitivity to the CCR5 antagonist maraviroc (MVC).
Results: Using a longitudinal panel of 244 R5 Envs cloned from 20 ART-naïve subjects with progressive C-HIV infec-
tion, we show that 40% of subjects (n = 8) harbored viruses that displayed incomplete inhibition by MVC, as shown 
by plateau’s of reduced maximal percent inhibitions (MPIs). Specifically, when pseudotyped onto luciferase reporter 
viruses, 16 Envs exhibited MPIs below 98% in NP2–CCR5 cells (range 79.7–97.3%), which were lower still in 293-Affino-
file cells that were engineered to express high levels of CCR5 (range 15.8–72.5%). We further show that Envs exhibit-
ing reduced MPIs to MVC utilized MVC-bound CCR5 less efficiently than MVC-free CCR5, which is consistent with the 
mechanism of resistance to CCR5 antagonists that can occur in patients failing therapy. Mutagenesis studies identified 
strain-specific mutations in the gp120 V3 loop that contributed to reduced MPIs to MVC.
Conclusions: The results of our study suggest that some ART-naïve subjects with C-HIV infection harbor HIV-1 with 
reduced MPIs to MVC, and demonstrate that the gp120 V3 loop region contributes to this phenotype.
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Background
Entry of human immunodeficiency virus type 1 (HIV-
1) into cells is mediated by the envelope glycoprotein 
complex (Env). Env exists as a trimer of heterodimers of 
gp120 surface and gp41 transmembrane glycoproteins 
that decorate the exterior of the virus particle (reviewed 
in [1]). Entry is initiated by the interaction between gp120 
and cell surface CD4 [2–4], followed by a secondary 
interaction with a chemokine coreceptor, either CCR5 or 
CXCR4 [5–9]. HIV-1 Envs are classified as CCR5-using 
(R5) or CXCR4-using (X4) depending on the choice of 
coreceptor used for entry. HIV-1 Envs that can interact 
with either CCR5 or CXCR4 to enter cells are referred to 
as dual-tropic (R5X4).
The interaction between gp120 and CD4 leads to con-
formational changes in gp120 affecting the first, second 
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and third variable loops (V1, V2, V3) and formation 
of the gp120 bridging sheet, which together comprise 
the coreceptor binding site (CoRbs) [10–12]. CCR5 is a 
G-protein coupled receptor that contains an N-terminal 
domain and 7 transmembrane helices, the latter of which 
forms a hydrophobic cavity at the cell membrane [13, 14]. 
The stem of the gp120 V3 loop and the bridging sheet of 
CD4-bound gp120 interact with the N-terminal domain 
of CCR5, and the tip of the V3 loop interacts with the 
second extracellular loop (ECL2) of the coreceptor [15–
17]. After coreceptor binding, further conformational 
rearrangements in gp41 occur that lead to virus-cell 
fusion and release of the viral core into the cell.
Maraviroc (MVC) is a CCR5 antagonist that is approved 
for use as an antiretroviral drug in treatment-experienced 
and -naïve HIV-1 infected subjects shown to harbour 
only R5 viruses [18–20]. Furthermore, since R5 HIV-1 
strains are preferentially transmitted from person to per-
son, MVC has potential for use in pre-exposure prophy-
laxis (PrEP) and microbicide formulations to prevent new 
infections [21–23]. Other experimental CCR5 antago-
nists that are not used clinically include vicriviroc (VVC) 
and aplaviroc (APL). MVC and other CCR5 antagonists 
inhibit HIV-1 entry by binding within the hydrophobic 
pocket of CCR5 [24–26], thereby altering the conforma-
tion of the CCR5 extracellular loops [27] such that they 
are no longer recognized by gp120. Consequently, MVC 
and other CCR5 antagonists are allosteric inhibitors of 
HIV-1 entry rather that competitive inhibitors.
Some HIV-1 infected subjects experience resistance to 
MVC after treatment with MVC-containing ART regi-
mens [18, 19]. There are two principal mechanisms that 
contribute to the emergence of MVC-resistant HIV-1 
strains in these subjects; (1) a selection for minor X4 
or R5X4 HIV-1 strains that are not inhibited by CCR5 
antagonists [19] or (2) acquisition of the ability of R5 
viruses to interact with the MVC-bound conformation of 
CCR5 [28–30]. In the latter scenario that typifies “genu-
ine” MVC resistance, the use of MVC-bound CCR5 by 
resistant viruses is characterized not by increases in the 
50% inhibitory concentrations (IC50) of MVC, but rather 
by reductions in the maximal percent inhibition (MPI) in 
viral infection assays, with plateaus of incomplete inhibi-
tion being evident despite saturating drug concentrations 
[28–30]. Considering the extensive variability of Env 
sequence between HIV-1 strains, and the inherently flex-
ible nature of coreceptor engagement by Env, we hypoth-
esized that the existence of clinical HIV-1 strains isolated 
from ART-naïve subjects that exhibited reduced MPIs 
to MVC was likely [31, 32]. In fact, recent studies have 
shown that Envs cloned from viruses isolated from treat-
ment-naïve individuals chronically infected with HIV-1 
subtype C (C-HIV), may be more efficient at interacting 
with MVC bound CCR5 than Envs from viruses isolated 
from subjects with acute infection [33, 34]. However, 
usage of MVC-bound CCR5 by viruses characterized in 
these studies was generally very inefficient compared to 
that which occurs in genuinely resistant HIV-1 strains 
isolated from patients failing MVC therapy. Whether 
such baseline usage of MVC-bound CCR5 develops fur-
ther at late stages of infection and occurs at potentially 
clinically relevant efficiencies is yet to be determined.
Globally C-HIV is the most rapidly spreading HIV-1 
subtype, yet paradoxically, it is less virulent than other 
subtypes ex  vivo [35, 36], suggesting unique molecu-
lar mechanisms that simultaneously impair fitness and 
facilitate favourable transmission events. A number of 
these unique features appear to involve the Env glyco-
proteins and entry mechanisms. For example, in con-
trast to HIV-1 subtype B infection where, if untreated, 
progression to advanced stages of infection is frequently 
accompanied by a switch in coreceptor usage from R5 to 
R5X4 or X4 variants (reviewed in [37]), in C-HIV infec-
tion the detection of R5X4 and X4 variants is relatively 
rare, even at late stages of infection ([38] and references 
within). Furthermore, R5 C-HIV strains have been shown 
to exhibit alterations in their efficiency of CCR5 and CD4 
usage [39], and usage of particular alternative coreceptors 
in  vitro [40–42]. Together, these features of may influ-
ence how C-HIV strains respond to inhibition by CCR5 
antagonists such as MVC.
In this study we investigated the frequency, efficiency 
and underlying Env determinants of HIV-1 strains with 
reduced MPIs to MVC within an ART-naïve, longitudi-
nal cohort of 20 subjects who progressed from chronic to 
late stages of C-HIV infection over a 3 year period [38]. 
By functionally characterizing 244 independent Envs 
derived from plasma of these subjects, we demonstrate 
that 8 subjects (40%) harbored HIV-1 strains that could 
interact with MVC-bound CCR5 resulting in reduced 
MPIs to MVC. We further show that these variants have 
strain-specific mutations in the gp120 V3 loop region 
that contribute to this phenotype. However, strains with 
reduced MPIs to MVC did not emerge more frequently 
at advanced infection compared to chronic infection, 
suggesting that they are not selected for during disease 
progression. Together, our findings suggest that some 
ART-naïve subjects infected with C-HIV harbor viruses 
that display altered sensitivity to MVC, which involves 




Written informed consent was provided by the subjects 
for the use of stored plasma samples (from which the Env 
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clones were derived), as stated previously [38]. Ethics 
approval for the use of these samples was granted by the 
Medical Research Council of Zimbabwe (MRCZ/A/918) 
and by the Central Medical Scientific Ethics Committee 
of Denmark (624-01-0031).
Cells
293T cells, and NP2-CD4/CCR5 cells [43] were main-
tained in Dulbecco’s Modified Eagles Medium (DMEM) 
supplemented with 10% (vol/vol) fetal calf serum (FCS) 
and 100 μg/ml of penicillin and streptomycin. CD4 selec-
tion in NP2 cells was maintained by 500 μg/ml of G418 
and CCR5 expression was maintained by 1  µg/ml of 
puromycin. 293-Affinofile cells [44] were maintained in 
DMEM supplemented with 10% (vol/vol) FCS, 100  μg/
ml of penicillin and streptomycin, 50 μg/ml of blasticidin 
and 200 μg/ml of G418.
Env clones
The sequences of the C-HIV Env clones used here have 
been reported previously [38], and their GenBank acces-
sion numbers are shown in Additional file 1: Table S1.
Production and titration of Env‑pseudotyped luciferase 
reporter viruses
Env-pseudotyped luciferase reporter viruses 
were produced by transfection of 293T cells with 
pCMVΔP1ΔenvpA, pHIV-1Luc, and pSVIII-Env plas-
mids using lipofectamine 2000 (Invitrogen) at a ratio 
of 1:3:1, as described previously [45, 46]. Supernatants 
were harvested 48 h later, filtered through 0.45 μM-pore 
size filters, and stored at −80 °C. The infectivity of virus 
stocks was determined by titration in NP2-CD4/CCR5 
cells. For subsequent infection experiments of all cell 
lines, viral input was normalized to 2 × 105 relative light 
unit (RLU) counts.
HIV‑1 inhibition assays
The sensitivity of Env-pseudotyped luciferase reporter 
viruses to inhibition by MVC was determined as 
described previously [29, 47, 48]. Briefly, to obtain 
293-Affinofile cells with a medium/high level of CD4 
and high level of CCR5 (termed CD4med/CCR5hi cells), 
293-Affinofile cells were induced for 20 h prior to seeding 
with 2.5 ng/ml of minocycline (for CD4 expression) and 
2.0 μM of Ponasterone A (for CCR5 expression). In our 
hands this produces a cell type that expresses approxi-
mately 180,000 molecules per cell of CD4 and approxi-
mately 95,000 molecules per cell of CCR5, as determined 
by quantitative flow cytometry (qFACS) as described 
previously [49]. NP2-CD4/CCR5 cells and 293-Affino-
file CD4med/CCR5hi cells (1 × 104 in 100 μl) were seeded 
in flat-bottom 96-well plates.  24  h later the media was 
removed from cells and replaced with 100  µl of fresh 
media with fivefold dilutions of MVC (at a × 2 concen-
tration) for 30 min at 37 °C. The concentration range for 
MVC was 5 μM to 0.064 nM. NP2-CD4/CCR5 cells and 
293-Affinofile CD4med/CCR5hi cells were inoculated with 
Env-pseudotyped luciferase reporter viruses in 100 μl for 
12 h at 37 °C. Following this, the inoculum was removed 
and replaced with fresh media. The inhibitor concentra-
tions were maintained throughout the subsequent cul-
ture period. Infected cells were incubated at 37  °C for a 
total of 72 h. The level of HIV-1 entry was measured by 
luciferase activity in cell lysates (Promega) according to 
the manufacturers protocol. Luminescence was meas-
ured using a FLUOStar microplate reader (BMG). Back-
ground activity was assessed by mock-infected cells and 
was subtracted from all wells. The amount of luciferase 
activity in cells treated with MVC was expressed as a 
percentage of that in untreated cells. The percentage of 
inhibition was calculated by subtracting this number 
from 100. The data were fitted with a nonlinear function, 
and alterations in inhibitor sensitivity were assessed by 
reductions in the MPI as described previously [47].
Measurement of CD4/CCR5 usage efficiency
293-Affinofile cells were infected with Env-pseudotyped 
luciferase reporter viruses as described previously [29, 
49]. Briefly, 48 populations of cells expressing different 
combinations of CD4 and CCR5 levels were generated by 
inducing cells with twofold serial dilutions of minocycline 
(0.156–5.0  ng/ml) and ponasterone A (0.0156–2.0  μM). 
CD4 and CCR5 concentrations were determined by quan-
titative flow cytometry (qFACS) as described previously 
[44, 50]. CD4 expression ranged from 1600 to 190,000 
molecules per cell; CCR5 expression ranged from 1500 
to 95,000 molecules per cell. The induced cell popula-
tions were then either left untreated or treated with 10 μM 
MVC for 30 min at 37 °C, after which they were inoculated 
with 2 × 105 RLU of Env-pseudotyped luciferase reporter 
viruses and were analyzed for levels of HIV-1 entry 72 h 
later as described above. In experiments using MVC-
treated cells, the MVC concentration was maintained 
throughout the culture period. The relative level of virus 
entry achieved by each Env was expressed as a percentage 
of that achieved in 293-Affinofile cells expressing the high-
est concentrations of CD4 and CCR5. For infections per-
formed in the presence of MVC, virus entry was expressed 
as a percentage of that achieved in untreated wells.
Env mutagenesis
Env mutants were generated with a Quick Change II site-
directed mutagenesis kits (Agilent Technologies) accord-
ing to the manufacturers’ protocol, and were verified by 
full-length sequencing.
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Results and discussion
Detection of incomplete inhibition by MVC in HIV‑1 strains 
from a treatment‑naïve, longitudinal cohort of subjects 
with progressive HIV‑1 subtype C infection
Recent cross sectional studies demonstrated levels of 
incomplete inhibition of C-HIV strains by MVC that 
differed between transmitted and chronic Envs [33, 34]. 
However, the levels of incomplete inhibition were gener-
ally relatively low, with the majority of Envs tested exhib-
iting residual entry levels of just 0.01–1.0% in NP2-CD4/
CCR5 cells in the presence of a saturating concentra-
tion of MVC [34]. Since the threshold for the laboratory 
diagnosis of clinical MVC-resistance in similar cell lines 
(U87-CD4/CCR5) is typically at 5% residual entry or 
above in the presence of MVC [51], whether levels of 
residual entry below 5% are clinically relevant remains to 
be determined.
To better understand the frequency and magnitude 
of residual entry by C-HIV strains in the presence of 
MVC that may arise in untreated subjects during pro-
gressive infection, we first screened the infectivity of 
244 R5 C-HIV Envs that were isolated from longitudi-
nal plasma samples of 20 ART-naïve subjects from rural 
Zimbabwe. These subjects progressed from chronic to 
advanced stages of infection over a 3  year period [38]. 
Figure 1 shows the percentage of residual entry of Env-
pseudotyped luciferase reporter viruses when inoculated 
onto NP2-CD4/CCR5 cells in the presence of saturating 
MVC (5 µM). For these and subsequent results, “E” refers 
to Envs cloned from plasma taken at study enrolment, “I” 
refers to Envs cloned at an intermediate sampling time-
point 1 year after study enrolment, and “F” refers to Envs 
cloned at the final timepoint 3  years after study enrol-
ment [38]. Controls included (1) luciferase viruses pseu-
dotyped with the R5 Envs ADA, YU2 or JRCSF, which 
as expected, exhibited levels of residual entry <0.04% 
indicative of MVC sensitivity; (2) virus pseudotyped with 
a MVC-resistant Env that was generated in vitro (MVC-
Res) [48] which, consistent with the results of previous 
studies [47] exhibited levels of residual entry between 
30 and 40%; and (3) virus pseudotyped with the parental 
Env to which MVC-Res was derived (MVC-Sens), which 
we have previously shown has a degree of inherent base-
line ability to interact with MVC-bound CCR5 [47], and 
consistent with those studies exhibited levels of residual 
entry ~2%. From the results of our control infections, and 
in consideration of thresholds applied for MVC-Sens Env, 
we applied a cutoff of >2% residual entry in these analy-
ses for the identification of C-HIV Env clones that may 
exhibit residual entry levels that could potentially be clin-
ically relevant.
Analysis of viruses pseudotyped with the C-HIV Envs 
showed that 8/20 subjects (40%) had Env variants that 
displayed residual entry levels >2% in the presence of satu-
rating MVC (Fig. 1). Residual entry levels ranged from 2.7 
to 20.3% (Table  1). Overall, there was no temporal pat-
tern for emergence of Envs displaying residual entry in the 
presence of MVC, with these Envs detectable within early, 
intermediate and final plasma samples. However, the num-
ber of Env clones tested at each of the timepoints was rela-
tively small, so further studies of greater numbers of Env 
clones may be required to observe a relationship between 
Envs displaying a residual entry phenotype and disease 
stage.
Together, our results show that a proportion of C-HIV 
Envs from our cohort is capable of mediating entry into 
NP2-CD4/CCR5 cells in the presence of MVC. Our 
results confirm the observations of others who have 
found a portion of acute disease-derived and chronic 
disease-derived Envs with similar phenotypes [33, 34]. 
Indeed both Parker et al. and Ping et al. found the residual 
entry in the presence of saturating MVC to be more fre-
quent in chronic disease-derived Envs. We have extended 
these observations by showing that this phenomenon 
does not appear to increase during the course of active 
disease as we found no difference in the proportion of 
the residual entry phenotype between the enrolment, 
intermediate and final timepoints. Interestingly, we have 
found that, at a population level, the ability of our panel 
of C-HIV Envs to utilise the alternative coreceptors CCR3 
and FPRL1 increased as disease advanced suggestive of 
alterations in the flexibility of Env to engage coreceptor 
[40]; the individual alternative coreceptor usage charac-
teristics of the Envs that display entry in the presence of 
MVC, in comparison to a representative Env from each 
subject that is completely inhibited by MVC, is shown in 
Additional file  2: Table  S2. Increased flexibility in core-
ceptor engagement has been observed previously in stud-
ies of disease progression in subtype B infection [52, 53], 
and this has been associated with reduced sensitivity to 
RANTES and TAK-779 as determined by increases in 
IC50 values [53, 54]. Recent evidence suggests that this is 
also the case for MVC [55]. Interestingly, MVC resistance 
is commonly associated with increased Env dependence 
on interactions with the CCR5 N-terminus, likely signal-
ling a movement toward regions of CCR5 not modified 
by MVC binding [29, 30, 48]. Conversely, reduced sensi-
tivity to MVC, as determined by increases in IC50/IC90, is 
associated with reduced dependence on the CCR5 N-ter-
minus [31, 55]. Taken together, our results suggest that 
increased flexibility of CCR5 usage may not necessarily 
lead to strains with reduced MPIs to MVC.
Whilst our data demonstrates the presence of C-HIV 
Envs with baseline reductions in MPI to MVC, there is 
evidence that this phenotype is not unique to C-HIV. 
Parker et  al. observed similar levels of reduced baseline 
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Fig. 1 Residual viral entry in the presence of saturating MVC in NP2-CD4/CCR5 cells infected with HIV-1 subtype C Envs from a longitudinal 
progressor study. Luciferase reporter viruses pseudotyped with HIV-1 subtype C Envs were used to infect NP2-CD4/CCR5 cells in the presence of 
saturating amounts of MVC. Residual entry was expressed as the percentage of entry achieved compared to no drug controls. The data points are 
means of triplicate wells. Dotted line, arbitrary cutoff value set by MVC-Sens residual entry; red dots, clones above cutoff and thus considered resist-
ant; black dots, clones below cutoff and thus considered sensitive. E enrolment timepoint, I intermediate timepoint, F final timepoint
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MPI in chronic-derived Envs from both B- and C-HIV 
[56]. In addition, the MVC-Sens control Env for our 
assays that displays reduced baseline MPI, is derived 
from the CC1/85 isolate, itself a B-HIV strain [28]. Thus, 
the phenomenon of baseline MPI reductions to MVC is 
unlikely to be limited to C-HIV and may be a more gen-
eral feature of chronic derived Envs.
Levels of incomplete HIV‑1 inhibition by MVC are more 
pronounced in 293‑Affinofile CD4med/CCR5hi cells
We have previously demonstrated that obscure or bor-
derline MVC resistance profiles seen in U87-CD4/CCR5 
and NP2-CD4/CCR5 cells are amplified in 293-Affinofile 
cells [47]. This may be related to a higher level of CCR5 
expression on 293-Affinofile cells engineered to express 
high levels of CCR5, or expression of conformations of 
CCR5 not bound by MVC [33, 47]. We therefore con-
ducted HIV-1 entry experiments in 293-Affinofile cells 
that were induced to express moderate CD4 levels and 
high CCR5 levels (293-Affinofile CD4med/CCR5hi), in the 
presence of saturating MVC (10 μM). Table 1 compares 
the residual entry in the presence of MVC between 
experiments conducted in NP2-CD4/CCR5 cells and 
293-Affinofile CD4med/CCR5hi cells. The residual entry 
levels in 293-Affinofile CD4med/CCR5hi cells by the 
Envs tested ranged from 27.5 to 84.2%, which are values 
approximately 7- to 20-fold greater than those derived 
from the NP2-CD4/CCR5 cell experiments. Importantly, 
control experiments with viruses pseudotyped with YU2 
and JRCSF Envs demonstrated residual entry levels <0.5% 
in 293-Affinofile CD4med/CCR5hi cells, confirming that 
293-Affinofile cells have greater sensitivity for detection 
of HIV-1 strains that are incompletely inhibited by MVC 
without compromising specificity.
Whilst the results of the preceding experiments dem-
onstrate the frequency and magnitude of C-HIV Envs 
displaying a residual entry despite a saturating concen-
tration of MVC, suggesting usage of MVC-bound CCR5 
for entry, bone fide MVC resistance is characterized by 
plateaus of incomplete inhibition in response to esca-
lating drug concentrations [28]. We therefore next per-
formed confirmatory titration experiments on 14 of the 
incompletely inhibited C-HIV Envs from 6 subjects, in 
293-Affinofile CD4med/CCR5hi cells, with comparison to 
a representative Env cloned from the same plasma sam-
ple that did not display residual entry in the presence of 
MVC (Fig. 2). As expected, most of the Envs that did not 
display residual entry in the presence of MVC achieved 
MPIs of ~100%; the exception to this was Env 550-I-2, 
which although completely inhibited by MVC in NP2-
CD4/CCR5 cells, displayed an MPI of 92.7% in 293-Affi-
nofile CD4med/CCR5hi cells (Fig. 2; Table 2). These results 
suggest that Env 550-I-2 may also possess a low level 
of altered MVC sensitivity that was not detected in the 
NP2-CD4/CCR5 cell screen. All the Envs that displayed 
residual entry despite MVC in both NP2-CD4/CCR5 
cells and 293-Affinofile CD4med/CCR5hi cells exhibited 
plateaus of incomplete inhibition in response to escalat-
ing MVC concentrations (Fig. 2), with MPIs ranging from 
27.5 to 72.6%. These MPIs are consistent with the defini-
tion of “moderate” to “low level” MVC resistance, respec-
tively, that has been determined for viruses isolated from 
patients failing MVC-containing ART regimens [29].
Our results with 293-Affinofile CD4med/CCR5hi cells 
demonstrate a striking phenotypic similarity between 
the Env clones with reduced MPIs to MVC that we have 
detected in treatment naïve individuals and Env clones 
isolated from individuals who have failed MVC therapy 
[29, 30]. Based on the plateaus in MPI in 293-Affinofile 
CD4med/CCR5hicells, the Env clones with reduced MPIs 
to MVC characterized here are likely interacting with 
MVC-bound forms of CCR5 and with an efficiency simi-
lar to strains with genuine resistance to MVC [29]. Our 
Table 1 Residual entry of  selected HIV-1 subtype C Envs 
in the presence of MVC in NP2-CD4/CCR5 and 293-Affino-
file CD4med/CCR5hi cells
n.a. not done
a Mean % residual entry ± standard deviation from two independent 
experiments




ADA 0.25 ± 0.04 n.a.
YU2 0.04 ± 0.02 0.26 ± 0.02
JRCSF 0.09 ± 0.02 0.18 ± 0.02
MVCres 37.8 ± 1.01 68.45 ± 14.35
MVCsens 1.82 ± 0.2 47.28 ± 2.23
204 E-7 3.6 ± 0.09 36.24 ± 5.01
550 I-2 3.80 ± 0.71 52.6 ± 13.87
I-7 3.84 ± 1.00 36.2 ± 1.81
F-12 4.32 ± 1.32 60.32 ± 7.20
F-20 2.80 ± 1.11 38.83 ± 4.09
1375 E-2 9.73 ± 2.50 84.20 ± 8.99
I-8 20.34 ± 5.23 69.03 ± 9.10
1441 E-1 5.70 ± 0.47 44.77 ± 2.55
E-2 2.7 ± 1.00 53.69 ± 9.14
E-6 6.72 ± 0.66 67.26 ± 9.58
I-2 3.90 ± 0.49 68.34 ± 11.52
I-9 4.57 ± 0.42 79.78 ± 4.18
1503 F-7 3.37 ± 0.71 n.a.
1684 E-7 2.84 ± 1.74 27.46 ± 3.51
1854 I-7 4.56 ± 0.73 n.a.
2042 I-38 2.95 ± 0.86 38.77 ± 0.53
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findings further highlight the efficiency of 293-Affinofile 
CD4med/CCR5hi cells in determining the magnitude of 
reduced MPIs by strains with altered MVC sensitivity. 
This may be due to the high levels of CCR5 expression 
on these cells when maximally induced with Ponas-
terone, higher than seen on other cell types [34, 47]. At 
high concentrations of MVC, this would lead to a greater 
density of MVC bound CCR5 leading to a more efficient 
interaction between CCR5 and MVC resistant gp120. 
Conversely, 293-Affinofle cells may express a minority 
population of CCR5 that cannot be bound by MVC but 
can be bound by gp120 [33]. This minority species may 
only become relevant when CCR5 expression is induced 
to high levels on these cells. The concept of distinct forms 
of CCR5 expressed on different cell types has been pro-
posed as a reason as to why CCR5 antagonist resistance 
manifests itself differently between primary CD4+ T 
cells and engineered cell lines such as TZM-bl [57]. Our 
results suggest that 293-Affinofile CD4med/CCR5hi cells 
may provide greater sensitivity for the detection of HIV-1 
strains that are incompletely inhibited by MVC.
The magnitude of reduced MPIs to MVC by C‑HIV Envs is 
related to the efficiency of usage of MVC bound CCR5
Envs displaying moderate to low level MVC resist-
ance have been shown to interact with the MVC-bound 
CCR5 complex relatively inefficiently compared to 
their interactions with drug-free CCR5 [47]. We there-
fore next used affinity profiling to quantify the ability of 
two C-HIV Envs, representing those with the highest 
(1684-E-7; MPI 72.6%) and lowest MPIs (1375-E-2; MPI 
16.5%) in response to escalating concentrations of MVC 
(Table  2), to interact with MVC-bound CCR5. To do 
this we used the 293-Affinofile affinity profiling system 
where CD4 and CCR5 levels are controlled by separate 
inducible promoters, permitting independent variation 
of CD4 and CCR5 expression over a physiological con-
centration range [50]. When 48 differentially induced 
cell populations are subjected to entry assays with Env 
pseudotyped luciferase viruses, relative efficiencies of 
CD4- and CCR5-usage can be inferred. Results of the 
affinity profiling experiments are shown in Fig.  3, and 
illustrate that in the absence of MVC, the Envs that are 
Fig. 2 MVC sensitivity curves in 293-Affinofile CD4med/CCR5hi cells. Luciferase reporter viruses were used to infect 293-Affinofile CD4med/CCR5hi cells 
in the presence of increasing concentrations of MVC. Data points represent the mean and standard error of infections performed in triplicate from 
one representative experiment. Viral inhibition curves were constructed as described in the “Methods”
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completely- or incompletely inhibited by MVC from both 
subjects have similar infectivity profiles suggesting simi-
lar usage efficiencies for both CD4 and CCR5. However, 
in the presence of MVC both of the incompletely inhib-
ited Envs required much higher levels of CCR5 to achieve 
detectable levels of entry. This was particularly the case 
for 1684-E-7 Env that displayed the highest MPI to MVC, 
which supports the conclusion that the magnitude of the 
reduced MPI to MVC is determined by the efficiency of 
the interaction with MVC-bound CCR5.
Amino acid determinants of HIV‑1 strains with reduced 
MPIs to MVC map to the V3 gp120 region and are 
subject‑specific in the C‑HIV cohort
As previous studies of B-HIV Envs have shown, changes 
in the gp120 V3 loop contribute to the emergence of 
resistance to CCR5-antagonist HIV-1 entry inhibitors 
[28, 29, 58]. To investigate the determinants that con-
tribute to reduced MPIs to MVC in treatment-naïve 
C-HIV infected subjects, we next analyzed V3 sequences 
of Envs that displayed plateaus below 100% in 293-Affi-
nofile CD4med/CCR5hi cells, compared to their corre-
sponding genetically-related Envs that were completely 
inhibited by MVC. For all subjects, the incompletely 
inhibited Envs displayed V3 sequences that differed from 
completely inhibited Envs recovered from the same sub-
jects (Fig. 4). For the subsequent analyses we focussed on 
subjects 1375 and 1141, primarily because the incom-
pletely inhibited Envs from these subjects displayed the 
lowest MPIs to MVC (Fig. 2) and had relatively consist-
ent and/or discrete patterns of V3 changes whose func-
tional properties could be more readily interrogated by 
mutagenesis studies (Fig. 4). Incompletely inhibited Envs 
from subject 1375 have a Gly residue at Env position 306, 
whereas completely inhibited Envs have Ser at this posi-
tion. Similarly, completely inhibited Envs from subject 
1441 possess Arg at position 305, whereas the majority 
of the incompletely inhibited Envs from subject 1441 
have Gln at position 305. Although distinguishing amino 
acid changes also occurred at positions 320 and 328 for 
subject 1441, we focussed on the distinguishing change 
at position 305 because previous studies have shown that 
mutations at this position can contribute to CCR5 antag-
onist resistance by clinical HIV-1 subtype C strains [51, 
53]. To determine if these V3 loop mutations conferred 
incomplete MVC inhibition, we created residue swap 
mutants introducing Ser at position 306 for the incom-
pletely inhibited Env 1375-E-2; Gly at position 306 for the 
completely inhibited 1375-E-21; Gln at position 305 for 
the completely inhibited Env 1441-E-7; and Arg at posi-
tion 305 for the incompletely inhibited Env 1441-E-6 
(Fig. 5). The mutant Envs retained an R5 phenotype when 
tested for infectivity on NP2-CD4/CCR5 and NP2-CD4/
CXCR4 cells (data not shown).
We next generated luciferase reporter viruses pseu-
dotyped with the Env mutants, and performed MVC 
sensitivity assays in 293-Affinofile CD4med/CCR5hi cells 
(Fig.  6). Introduction of Gly306 into the completely 
inhibited 1375-E-21 Env led to a modest reduction in 
MPI from 98.3 ± 1.9 (mean % ±  standard deviation) to 
92.2 ± 0.5; whilst introduction of Ser306 into the incom-
pletely inhibited 1375-E-2 Env led to an increase in MPI 
from 36.1 ±  2.9 to 86.7 ±  2.4 and thus, partial restora-
tion of MVC sensitivity. Similarly, introduction of Gln305 
into the completely inhibited 1441-E-7 Env made no 
appreciable difference in MPI (101.3 ± 1.6 to 99.9 ± 0.6), 
and introduction of Arg305 into the incompletely inhib-
ited 1441-E-6 Env completely restored MVC sensitivity 
(67.4 ± 4.0 to 100.4 ± 1.2). These results suggest that for 
the Envs tested, V3 loop mutations are necessary but not 
sufficient for baseline incomplete HIV-1 inhibition by 
MVC, and that these mutations are strain specific.
Multiple studies have shown that the primary determi-
nants of HIV-1 resistance to CCR5 antagonists lie within 
the V3 loop of gp120 [28–30, 59–63]. In agreement with 
these studies, our results show that single V3 loop muta-
tions are necessary for incomplete inhibition by MVC 
Table 2 Maximal percent inhibition (MPI) of selected HIV-1 
subtype C Envs by  maraviroc in  293-Affinofile CD4med/
CCR5hi cells
MPI maximal percent inhibition, SD standard deviation
a Mean and b standard deviation of three independent experiments
Patient ID Env clone MPI (%)a SD (%)b
204 E-15 100.13 1.66
E-7 68.65 16.62





1375 E-21 100.01 0.69
E-2 16.54 10.53
I-8 30.87 9.17






1684 I-13 100.27 1.46
E-7 72.63 2.91
2042 E-26 100.99 1.57
I-38 63.55 1.30
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for the C-HIV Envs studied. However, the single V3 
loop mutations were not sufficient to confer the incom-
plete inhibition phenotype suggesting that additional 
mutations outside of V3 may be required. This has been 
observed in other CCR5 antagonist resistant strains [29, 
57, 58]. Furthermore, we showed that amino acid muta-
tions important for incomplete MVC inhibition were 
strain specific, which is commonly observed amongst 
CCR5 antagonist resistant strains generated in vitro and 
in vivo [28, 29, 57, 58, 64].
Conclusions
Our results demonstrate the presence of HIV-1 Env 
glycoproteins that display incomplete inhibition to the 
CCR5 antagonist MVC in a proportion of the ART-naïve 
subtype C infected individuals from our cohort. The 
incomplete inhibition profiles we describe are similar in 
mechanism to those seen in Envs isolated from individu-
als who fail MVC-containing therapy, which most likely 
involves the use of the MVC-modified form of CCR5 for 
entry. Furthermore, similar to genuine MVC-resistant 
strains, we were able to map residues critical for incom-
plete inhibition to the V3 loop of gp120. In agreement 
with our previous studies [29, 47] and those of other 
investigators [33, 34] on CCR5 antagonist resistance, we 
demonstrated that incomplete MVC inhibition profiles 
are more readily apparent in 293-Affinofile cells induced 
to express high levels of CCR5. Whether the C-HIV 
strains described here with incomplete MVC inhibi-
tion may act as scaffolds for the generation of genuine 
MVC resistance during MVC containing ART regimens 
is a possibility that remains to be determined by further 
studies.
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loop amino acid sequences of Env clones displaying incomplete inhibition by MVC and one representative Env clone displaying complete inhibi-
tion are shown from 6 subjects. Dots indicate residues identical to the representative sensitive clone and dashes indicate gaps. The numbering is 
based on the HXB2 Env amino acid sequence. Sens: Representative Env clone displaying complete inhibition by MVC, Res: Envs clones that display 
incomplete inhibition by MVC
Fig. 5 V3 loop amino acid sequence of Env mutants. The V3 loop 
sequences from the parental and mutant Env clones from two indi-
viduals are shown. The amino acid alterations are shown in red. Dots 
indicate residues identical to the parental strain and dashes indicate 
gaps. The numbering is based on the HXB2 Env amino acid sequence
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